Esperion (ESPR) AI Stock Analysis

• Market Cap: $772.17M
• Dividend Yield: N/A
• Average Volume (3M): 5.15M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.36
• Revenue Growth: 2.83%
• EPS Growth: 13.61%
• Country: US
• Employees: 304
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.16
• Shares Outstanding: 239,063,430
• 10 Day Avg. Volume: 5,703,794
• 30 Day Avg. Volume: 5,152,300
• PEG Ratio: 0.09
• Price to Book (P/B): -1.06
• Price to Sales (P/S): 1.24
• P/FCF Ratio: -17.18
• Enterprise Value/Market Cap: 1.34
• Enterprise Value/Revenue: 3.41
• Enterprise Value/Gross Profit: 6.38
• Enterprise Value/Ebitda: -37.95
• 1Y Price Target: $7.94
• Price Target Upside: 153.80% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): 0.09
• Revenue Forecast (FY): $380.09M

• Rating: 46 Neutral
• Price Target: $3.00 ▼(-4.15% Downside)

The score is held down primarily by weak financial fundamentals—negative equity, sizable leverage, and ongoing cash burn despite improving revenues and narrower losses. Technicals are also soft in the near term (price below short-term averages with low RSI), while valuation provides limited support due to losses and no dividend data. The earnings call was a clear positive with strong growth and franchise protection (generic delay to 2040), but it is not yet sufficient to offset the balance-sheet and cash-flow risks.

Positive Factors

Long-term franchise protection

Securing exclusivity until 2040 materially reduces the risk of near- and mid-term generic erosion, preserving a predictable revenue runway for Nexletol/Nexlizet. This structural protection supports investment in commercialization and pipeline development over many years.

Rapid recent revenue and commercial traction

Strong top-line acceleration and sequential prescription growth indicate scalable commercial execution and growing market penetration. Durable revenue momentum from both product and collaboration channels supports a path toward profitability if sustained.

Strategic partnerships and international growth

Meaningful international partnerships diversify revenue streams and lower commercialization risk outside the U.S. Recurring royalty income and upcoming launches in large markets strengthen long-term growth prospects and reduce dependence on a single geography.

Negative Factors

Highly stressed balance sheet

Material leverage and negative equity substantially constrain financial flexibility. Elevated refinancing and dilution risk can force costly capital raises or limit strategic investments, impeding the company’s ability to fund commercialization and R&D without shareholder dilution.

Persistent negative cash generation

Sustained cash burn requires ongoing external financing and raises execution risk. Negative FCF limits the company’s ability to self-fund growth initiatives, heightens sensitivity to capital markets conditions, and can force trade-offs between commercial investment and pipeline funding.

Continued unprofitable operations

Ongoing losses and compressed gross margins mean the business has not reached sustainable profitability. If margins fail to recover, the company may struggle to generate internal funds for expansion, making long-term viability contingent on margin improvement or external capital.

Esperion Business Overview & Revenue Model

Company Description

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

How the Company Makes Money

Esperion generates revenue primarily through the sale of its pharmaceutical products, particularly Nexletol. The company's revenue model is driven by product sales to healthcare providers, hospitals, and pharmacies. Additionally, Esperion may engage in partnerships and collaborations with other pharmaceutical companies to co-promote products or share research and development costs. Significant partnerships can enhance distribution and marketing efforts, potentially leading to increased sales. The company may also receive milestone payments and royalties from licensing agreements related to its drug development initiatives.

Esperion Financial Statement Overview

Summary

Esperion's financial performance is challenged by significant profitability and financial stability issues. Despite strong revenue growth, the company faces negative net profit margins and negative equity, indicating high financial risk and leverage.

Income Statement

Esperion has shown significant revenue growth from 2023 to 2024, with a Revenue Growth Rate of 185.6%. However, the company is still facing challenges with profitability as indicated by the negative Net Profit Margin of -15.6% in 2024. The Gross Profit Margin improved to 79.3%, but the negative EBIT and EBITDA margins reflect ongoing operational challenges.

Balance Sheet

The balance sheet reveals a concerning negative Stockholders' Equity of -$388.7 million, indicating financial instability. The Debt-to-Equity Ratio is not calculable due to negative equity, highlighting high leverage. The Equity Ratio is also negative, suggesting that liabilities exceed assets, which poses a significant risk.

Cash Flow

Esperion's cash flow situation is challenging, with a negative Free Cash Flow of -$23.97 million in 2024. The Operating Cash Flow to Net Income Ratio is negative, indicating cash flow issues relative to net losses. However, the company has managed to reduce its negative Free Cash Flow compared to previous years, showing some improvement.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	303.80M	332.31M	116.33M	75.47M	78.45M	227.55M
Gross Profit	162.67M	263.71M	73.07M	48.51M	64.23M	225.16M
EBITDA	-27.34M	7.57M	-150.11M	-176.35M	-222.14M	-120.33M
Net Income	-105.83M	-51.74M	-209.25M	-233.66M	-269.11M	-143.55M
Balance Sheet
Total Assets	364.02M	343.82M	205.80M	247.94M	381.59M	353.26M
Cash, Cash Equivalents and Short-Term Investments	92.45M	144.76M	82.25M	166.86M	259.33M	304.96M
Total Debt	600.99M	591.21M	540.95M	260.95M	260.20M	185.41M
Total Liabilities	815.38M	732.54M	660.79M	571.72M	578.53M	449.39M
Stockholders Equity	-451.36M	-388.72M	-454.99M	-323.78M	-196.94M	-96.13M
Cash Flow
Free Cash Flow	-93.29M	-23.97M	-135.49M	-174.83M	-263.81M	-98.55M
Operating Cash Flow	-93.29M	-23.65M	-135.49M	-174.83M	-263.81M	-85.18M
Investing Cash Flow	0.00	-317.00K	42.50M	8.10M	-50.48M	21.36M
Financing Cash Flow	41.02M	86.48M	50.46M	32.61M	268.22M	201.72M

Esperion Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 3.13
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ESPR, the sentiment is Neutral. The current price of 3.13 is below the 20-day moving average (MA) of 3.73, below the 50-day MA of 3.51, and above the 200-day MA of 2.14, indicating a neutral trend. The MACD of -0.07 indicates Positive momentum. The RSI at 34.60 is Neutral, neither overbought nor oversold. The STOCH value of 18.72 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ESPR.

Esperion Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SIGA	77 Outperform	$481.23M	6.35	39.94%	―	-0.85%	-13.50%
EBS	59 Neutral	$658.60M	8.46	13.92%	―	-29.91%	―
ORGO	52 Neutral	$491.15M	-40.47	0.30%	―	2.24%	-67.56%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
EOLS	50 Neutral	$325.40M	-5.48	―	―	15.10%	0.18%
SNDL	48 Neutral	$419.72M	-6.44	-7.82%	―	1.76%	18.31%
ESPR	46 Neutral	$772.17M	-5.84	―	―	2.83%	13.61%

Esperion Corporate Events

Esperion Appoints New Chief Commercial Officer

On November 4, 2025, Esperion Therapeutics announced the appointment of John B. Harlow, Jr. as the new Chief Commercial Officer, effective November 17, 2025. Harlow, who previously served as Chief Commercial Officer at Melinta Therapeutics, brings extensive experience in driving commercial strategies and enhancing sales and marketing performance. His appointment is expected to play a crucial role in expanding the adoption of Esperion’s cardiovascular risk reduction therapies and increasing the company’s global presence. Harlow’s leadership is anticipated to accelerate the delivery of innovative therapies to patients worldwide, furthering Esperion’s growth and market impact.

The most recent analyst rating on (ESPR) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Esperion stock, see the ESPR Stock Forecast page.